In a recent strategic progress update, NewGenIvf Group Limited (NASDAQ: NIVF) has witnessed a notable surge in its stock price. As of the latest market check, NIVF shares have climbed 24.65%, trading at $1.05 on the US stock charts.
- Advancing The Proposed Reverse Merger
- Details Of The Proposed Transaction
Advancing The Proposed Reverse Merger
NewGenIvf (NIVF) has announced ongoing active evaluations of the proposed reverse merger with COVIRIX Medical Pty Ltd. In order to meet the requirements needed for the Proposed Transaction to close, both firms have thoroughly investigated each other's businesses and are still making great progress in that direction.
By the end of August 2024, the firms want to have the non-binding term sheet completed for this deal. During the due diligence phase, COVIRIX disclosed that its treasury holds a crypto asset of substantial market value, nearly equivalent to NewGenIvf's current market capitalization. This asset has the potential to provide significant financing support for COVIRIX's drug development program.
Concurrently, NewGenIvf has secured a contract with a channel dealer to order a substantial volume of IVF treatments and surrogacy services through the end of 2025. This contract signifies a strong vote of confidence in NewGenIvf's capabilities and underscores the company's commitment to maximizing shareholder value through strategic opportunities, including the proposed COVIRIX reverse merger.
Details Of The Proposed Transaction
According to the Term Sheet, NewGenIvf proposes to issue 102,890,000 of its ordinary shares to the shareholders of COVIRIX or their nominees in exchange for a 100% equity interest in COVIRIX, at an implied price of US$6 per share, amounting to a total of US$617,340,000.
Concurrently, COVIRIX intends to raise US$6 million at the same share price for NIVF, in a form agreeable to both parties. Upon stockholder approval of the Proposed Transaction, COVIRIX shareholders are anticipated to hold approximately 85.8% equity interest in NewGenIvf. Additional details regarding the Proposed Transaction will be announced once a definitive agreement is executed.
新生IVF Group Limited (纳斯达克：NIVF) 最近发布了战略进展公告，该公司股票价格出现了显著飙升。截至最新市场检查，NIVF股票上涨了24.65%，在美国股票图表上交易价格为$1.05。
推进拟议的反向合并
NewGenIvf (NIVF) 已宣布正在积极评估与COVIRIX Medical Pty Ltd的拟议反向合并。为了达成拟议交易的要求，两家公司已经彼此深入调查对方的业务，并且在这个方向上仍在取得良好的进展。
截至2024年8月底，两家公司希望完成关于该交易的非约束性条款。在尽职调查阶段，COVIRIX披露其库存有一个大市值（几乎等同于NewGenIvf当前市值）的加密资产，这个资产有潜力为COVIRIX的药品开发计划提供重要的融资支持。
同时，NewGenIvf已与渠道经销商签署合同，以订购大量的IVF治疗和代孕服务，该合同标志着对NewGenIvf能力的强烈信心，并强调了该公司致力于通过战略机会（包括拟议的COVIRIX反向合并）最大化股东价值。
拟议交易的细节
根据条款表，NewGenIvf拟发行102,890,000股普通股，以每股6美元的含义价格，换取COVIRIX100%的股权，总数为6.1734亿美元，发给COVIRIX股东或其提名人。与此同时，COVIRIX打算以同样的股价为NIVF筹集600万美元，以得到双方都同意的形式。在股东批准拟议交易之后，预计COVIRIX股东将持有NewGenIvf大约85.8%的股权。一旦签署了最终协议，将公布有关拟议交易的其他细节。
同时，COVIRIX打算以同样的股价为NIVF筹集600万美元，以得到双方都同意的形式。在股东批准拟议交易之后，预计COVIRIX股东将持有NewGenIvf大约85.8%的股权。一旦签署了最终协议，将公布有关拟议交易的其他细节。
